The genetic basis to prostate cancer has been well established. Within the past several years, it has become evident that mutations and variations within germline DNA predispose to prostate cancer and lethal disease. Knowledge of these mutations can help guide screening, biopsy and treatment decisions. In addition, genomic based tests (e.g. RNA based assays including Oncotype Dx, Prolaris and Decipher) have also become available which can help guide treatment decisions for men considering active surveillance. Some of these tests can help guide decisions for additional therapy after surgery. Together these genomic based tests should be utilized to provide personalized care for prostate cancer.

Continuing Education Instructions and Disclosure Information

Contact hours available until 3/23/21.

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation. You will be able to print your CNE certificate at any time after you complete the evaluation.

Planning Committee Disclosures:
Kathy Marchese, ANP, NP, CWOCN

Speakers Bureau - Hollister (non-branded lecture on Intermittent Catheterizaiton)

There are no other disclosures to declare.

Speakers Conflict of Interest Disclosure:
Brian Helfand, MD, PhD

Speakers Bureau - Ambry Genetics

There are no other disclosures to declare.

Commercial Support and Sponsorship:
No commercial support or sponsorship declared.

Accreditation Statement:
Society of Urologic Nurses and Associates (SUNA) is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The SUNA accreditation is reciprocal in the states and specialty organizations that recognize the ANCC-COA accreditation process. SUNA is also a provider approved by the California Board of Registered Nursing, Provider Number CEP 5556. Accreditation and approved provider status of CE in nursing does not imply ANCC-COA approval or endorsement of any product, advertising, or educational content. SUNA urges all participants to be aware of the CE requirements for re-licensure in the states in which they hold a license.

Learning Outcome:
After completing this continuing education activity, the learner will be able to understand the rationale for genetic testing and identify which germline variants are associated with prostate cancer susceptibility and increased risk of aggressive cancer as well as the implications for screening and treatment decisions.

Brian Helfand MD, PhD

Appearances